TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications

International Angiology

Volumn 24, Issue 4, 2005, Pages 366-371

  Novo, G ^a   Caplice, N ^b   Tantillo, R ^a   Bonura, F ^a   Simari, R ^b   Novo, S ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; Carotid diseases; Cerebrovascular accident; Myocardial infarction; Peripheral arterial diseases; Stroke; TFPI activity; TFPI antigen

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE DISEASE; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; STROKE; UNITED STATES; VASCULAR DISEASE;

ADULT; AGED; ANTIGENS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 30844456407     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hjort PF. Intermediate reactions in coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957;9 Suppl:1-182.
2. Broze G. The role of TFPI in a revised coagulation cascade. Semin Haematol 1992;29:159-69.
3. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002;22:539-48.
4. McGee MP, Foster S, Wang X. Simultaneous expression of TFPI by human monocyte. A potential mechanism for localized control of blood coagulation. J Exp Med 1994;179:1847-54.
5. Wun TC, Huang MD, Kretzmer KK, Palmier MO, Day KC, Bulock JW et al. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells. A comparative study. J Biol Chem 1990;265:16096-101.
6. Broze GJ, Militech JP. Isolation of TFPI produced by HepG2 Hepatoma cells. PNAS USA 1987;84:1886-90.
7. Ott I, Andrassy M, Zieglgansberger D, Geith S, Schomig A, Neumann FJ. Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1. Blood 2001;97:3721-6.
8. Iversen N, Sandset PM, Abilgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to endothelial cells: influence of glycosaminoglycans. Thromb Res 1996;84:267-78.
9. Novotny WF, Girard TJ, Militech JP, Broze GJ. Purification and characterization of lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989;264:18832-7.
10. Broze GJ Jr, Lange GWW, Duffin KL, Mac Phail. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinol 1994;2:713-21.
11. Kawaguchi A, Miyao Y, Noguchi T, Nonogi H, Yarnagishi M, Miyatake K et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000;20:251-8.
12. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988;72:2020-5.
13. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M et al. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001;85:999-1003.
14. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002;22:539-48.
15. Frohlich ED, Grim C, Labarthe DR. Recommendations for human blood pressure determination by sphygmomanometers. Circulation 1988;77:502a-14a.
16. Schmidt FH, Pfeiffer EE Handbuch des diabetes mellitus. In: Lehmans JF, editor. Munchen: Verlag; 1971.p. 938-42.
17. Roschlau. P, Bernt E, Gruber W. [Enzymatic determination of total cholesterol in serum (author's transl)]. Z Klin Chem Klin Biochern 1974; 12:403-7.
18. Wahalefeld AW. Triglyceride determination after enzymatic hydrolysis. New York: Academic Press; 1974.p1831-5.
19. Lopez-Virella HF, Stone P, Ellis J, Coltwell LA. Cholesterol determination in the HDL separated by precipitation with polianions. J Lipid Res 1970; 11:583-95.
20. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196:561-4.
21. Salonen R, Salonen TJ. Progression of carotid atherosclerosis and its determinants in a population ultrasonography based study. Atherosclerosis 1990;81:33-40.
22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-406.
23. Novo S, Pernice C, Barbagallo CM, Tantillo R, Caruso R, Longo B. Influence of risk factors and aging on asymptomatic carotid lesions. In: Nicolaides A, Novo S, editors. Advances in vascular pathology 1997. International Congress Series 1150. Amsterdam: Elsevier, Excerpta Medica; 1997.p.33-44.
24. Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1995;6 Suppl 1:S65-72.
25. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J et al.; PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109:1343-8.
26. He M, Wen Z, He X, Xiong S, Liu F, Xu J et al. Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases. Thromb Res 2002;107:223-8.
27. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001;98:2980-7.
28. Blann AD, Amiral J, McCollum CN, Lip GY Differences in free and total tissue factor pathway inhibitor, and tissue Factor in peripherul artery disease compared to healthy controls. Atherosclerosis 2000;152:29-34.
29. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999;10 Suppl 1:S9-12.
30. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698-704.
31. Lorena M, Perolini S, Casazza F, Milani M, Cimminiello C. Fluvastatin and TFPI in type IIa and IIb hyperlipidemia and in acute myocardial infarction. Thromb Res 1997;87:397-403.
32. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H et al. Increased TFPI in patients with acute myocardial infarction. Am J Haematol 1997;55:183-7.
33. Liu Y, Stack SM, Lakka SS, Khan AJ, Woodley DT, Rao JS et al. Matrix localization of tissue factor pathway inhibitor-2/matorix-associated serine proteinase inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arc Biochem Biophys 1999;370:112-8.